中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
26期
36-37
,共2页
精神分裂症%阴性症状%奥氮平%利培酮
精神分裂癥%陰性癥狀%奧氮平%利培酮
정신분렬증%음성증상%오담평%리배동
Schizophrenia%Negative symptoms%Olazepine%Risperidone
目的：观察研究奥氮平与利培酮对精神分裂症患者阴性症状的疗效和安全性。方法将70例以阴性症状为主的住院精神分裂症患者随机分为奥氮平组（35例）与利培酮组（35例），疗程12周。采用阳性与阴性症状量表（PANSS）及副反应量表（TESS）对照评定疗效和不良反应。结果奥氮平组与利培酮组分别为74.2%、71.4%，差异无显著性（P＞0.05）。两组不良反应发生率分别为37.1%和34.2%，差异无显著性（P＞0.05）。结论奥氮平治疗精神分裂症阴性症状的疗效及安全性总体上与利培酮相当。
目的：觀察研究奧氮平與利培酮對精神分裂癥患者陰性癥狀的療效和安全性。方法將70例以陰性癥狀為主的住院精神分裂癥患者隨機分為奧氮平組（35例）與利培酮組（35例），療程12週。採用暘性與陰性癥狀量錶（PANSS）及副反應量錶（TESS）對照評定療效和不良反應。結果奧氮平組與利培酮組分彆為74.2%、71.4%，差異無顯著性（P＞0.05）。兩組不良反應髮生率分彆為37.1%和34.2%，差異無顯著性（P＞0.05）。結論奧氮平治療精神分裂癥陰性癥狀的療效及安全性總體上與利培酮相噹。
목적：관찰연구오담평여리배동대정신분렬증환자음성증상적료효화안전성。방법장70례이음성증상위주적주원정신분렬증환자수궤분위오담평조（35례）여리배동조（35례），료정12주。채용양성여음성증상량표（PANSS）급부반응량표（TESS）대조평정료효화불량반응。결과오담평조여리배동조분별위74.2%、71.4%，차이무현저성（P＞0.05）。량조불량반응발생솔분별위37.1%화34.2%，차이무현저성（P＞0.05）。결론오담평치료정신분렬증음성증상적료효급안전성총체상여리배동상당。
Objective?To assess the efficacy and safety of olazepine and risperidone in the treatment of schizophrenia with predominantly negative symptoms. Methods 70 schizophrenia patients with predominantly negative symptoms were randomly assigned to olazepine group (n=35) and risperidone group (n=35) for 12 weeks. The efficacy and side effects were evaluated with positive and negative symptom scale (PANSS) and treatment emergent symptom scales (TESS). Results There was no significant difference in efficacy between the two groups (74.2%vs 71.4%, P>0.05). Both groups had no significant difference in the overall adverse reactions (37.1%, 34.2%, P>0.05). Conclusion Olazepine is effective and safe in treatment of negative symptoms of schizophrenia as risperidone.
